Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Anti-Infective Agents

Dexamethasone

Lenalidomide

Pomalidomide

Dexamethasone acetate

Elotuzumab

Proteasome Inhibitors

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

HIV Protease Inhibitors

Protease Inhibitors

Enzyme Inhibitors

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)

Elotuzumab in combination with pomalidomide and dexamethasone

Elotuzumab in combination with lenalidomide and dexamethasone

BMS Study Connect Contact Center www.BMSStudyConnect.com

First line of the email MUST contain NCT # and Site #.

Site 0002

Site 0003

Shang-Yi Huang, Site 0001

Site 0004

Bristol-Myers Squibb

This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan

Opportunistic infections including viral hepatitis and tuberculosis reactivation

Laboratory abnormality and/or adverse event

Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Elotuzumab in combination with Lenalidomide and Dexamethasone

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.

Expanded Access Treatment Protocol CA204-143

An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan	NCT06163040	Relapsed or Ref...	Elotuzumab in c... Elotuzumab in c...	18 Years -	Bristol-Myers Squibb
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan	NCT06163040	Relapsed or Ref...	Elotuzumab in c... Elotuzumab in c...	18 Years -	Bristol-Myers Squibb
Expanded Access Treatment Protocol CA204-143	NCT02368301	Multiple Myelom...	Elotuzumab in c...	18 Years -	Bristol-Myers Squibb
Expanded Access Treatment Protocol CA204-143	NCT02368301	Multiple Myelom...	Elotuzumab in c...	18 Years -	Bristol-Myers Squibb

Spots Global Cancer Trial Database for elotuzumab in combination with lenalidomide and dexamethasone